Galapagos increases share capital through subscription right exercises
May 28 2020 - 4:01PM
Galapagos increases share capital through subscription right
exercises
Mechelen, Belgium; 28 May 2020, 22.01 CET;
regulated information – Galapagos NV (Euronext & NASDAQ: GLPG)
announces a share capital increase arising from subscription right
exercises.
Galapagos issued 435,540 new ordinary shares on
28 May 2020, for a total capital increase (including issuance
premium) of €17,914,162.40.
CEO Onno van de Stolpe exercised 40,000
subscription rights. Four other management board members exercised
an aggregate number of 345,000 subscription rights. In addition,
one member of the supervisory board exercised 2,520 subscription
rights.
In accordance with Belgian transparency
legislation1, Galapagos notes that its total share capital
currently amounts to €352,968,964.92, the total number of
securities conferring voting rights amounts to 65,254,562, which is
also the total number of voting rights (the “denominator”), and all
securities conferring voting rights and all voting rights are of
the same category. The total number of rights (formerly known as
warrants) to subscribe to not yet issued securities conferring
voting rights is (i) 4,948,307 subscription rights under several
outstanding employee subscription right plans, which equals
4,948,307 voting rights that may result from the exercise of those
subscription rights, and (ii) two warrants issued to Gilead
Therapeutics to subscribe for a maximum number of shares that is
sufficient to bring the shareholding of Gilead and its affiliates
to 25.1% and 29.9%, respectively, of the actually issued and
outstanding shares after the exercise of the relevant warrant. This
excludes the 2,280,500 subscription rights of Subscription Right
Plan 2020 and Subscription Right Plan 2020 RMV, which were created
subject to acceptance. Galapagos does not have any convertible
bonds or shares without voting rights outstanding.
About GalapagosGalapagos
(Euronext & NASDAQ: GLPG) discovers and develops small molecule
medicines with novel modes of action, three of which show promising
patient results and are currently in late-stage development in
multiple diseases. Our pipeline comprises Phase 3 through to
discovery programs in inflammation, fibrosis, osteoarthritis and
other indications. Our ambition is to become a leading global
biopharmaceutical company focused on the discovery, development and
commercialization of innovative medicines. More information at
www.glpg.com.
Contacts
Investors:Elizabeth GoodwinVP Investor
Relations +1 781 460 1784
Sofie Van GijselDirector Investor Relations+32 485 19 14
15ir@glpg.com
Media:Carmen VroonenSenior Director
Communications & Public Affairs+32 473 824 874
Evelyn FoxDirector Communications +31 6 53 591 999
communications@glpg.com
Forward-looking statements
This release may contain forward-looking
statements. Such forward-looking statements are not guarantees of
future results. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly
disclaims any obligation to update any forward-looking statements
in this document, unless specifically required by law or
regulation.
1 Belgian Act of 2 May 2007 on the disclosure
of major shareholdings in issuers whose shares are admitted to
trading on a regulated market
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024